Atlas.
Sign inStart free trial
HAENASDAQ · US

HAEMONETICS CORP

Technology · Surgical & Medical Instruments & Apparatus

TechnologySurgical & Medical Instruments & Apparatus
CEO
Christopher A. Simon
Founded
—
IPO Date
—
HQ
Boston, MA, United States
Exchange
NYSE
Employees
n.a.

Share Price Performance

$74.85 ▼ 6.4%
Last (1 Jul 2026) · $75
Period High · $84.04
Period Low · $52.24
52W: $47.67 – $87.16

Key Metrics

Share Price
$74.85
-0.2% today
Market Cap
$3.5B
P / E
35.7x
EV / Revenue
3.4x
Revenue Growth
-2.0%
year-on-year
Gross Margin
+59.0%
Enterprise Value
$4.5B
52W High
$87.16
52W Low
$47.67
Avg Volume
773K
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
6 known institutional holders·$142M total on record·2026-Q1
BlackRock, Inc.
138.0%·$61M
Invesco Ltd.
127.4%·$56M
State Street Corp
33.1%·$15M
Fmr LLC
16.5%·$7M
Jpmorgan Chase & Co
4.5%·$2M
Bank Of America Corp
2.4%·$1M

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for HAEMONETICS CORP
OverviewHAEMONETICS CORP share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow HAEMONETICS CORP generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsHAEMONETICS CORP's complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityHAEMONETICS CORP executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsHAEMONETICS CORP's annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for HAEMONETICS CORP, updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for HAEMONETICS CORP aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersHAEMONETICS CORP valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for HAEMONETICS CORP with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for HAEMONETICS CORP — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial